Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.36 |
| ▸ | USP2 | O75604 | 6/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3879772 | 0.84 | L3MBTL1 (0.44) | ALDH1A1HSD17B10CYP2D6TSHRCYP2C19 | |
| SCHEMBL3878394 | 0.83 | UBE2M (0.36) | ALDH1A1HSD17B10CYP1A2TSHRCYP3A4 | |
| SCHEMBL3884855 | 0.83 | GRM5 (0.32) | ALDH1A1HSD17B10CYP1A2TSHRCYP3A4 | |
| SCHEMBL3882219 | 0.83 | ALDH1A1 (0.40) | ALDH1A1HSD17B10HPGDCYP2D6CYP1A2 | |
| SCHEMBL3885757 | 0.82 | GRM5 (0.37) | ALDH1A1 | |
| SCHEMBL3882841 | 0.82 | UBE2M (0.33) | ALDH1A1HSD17B10CYP1A2TSHRCYP3A4 | |
| SCHEMBL3879091 | 0.82 | UBE2M (0.41) | ALDH1A1HSD17B10CYP2D6CYP1A2TSHR | |
| SCHEMBL3878678 | 0.81 | GRM5 (0.43) | ALDH1A1HSD17B10CYP2D6TSHRSMN1; SMN2 | |
| SCHEMBL3878476 | 0.81 | RBP4 (0.43) | — | |
| SCHEMBL3878879 | 0.81 | SMN1; SMN2 (0.38) | ALDH1A1HSD17B10CYP1A2TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858900-B1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-01-07 | — | — | EP | claimed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | claimed |
| EP-1858900-B1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-01-07 | — | — | EP | disclosed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | HRH3, HRH4, HRH2 | ALDH1A1 1866/4885HSD17B10 2770/4885HPGD 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.